ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schreurs, A.
Right arrow Articles by Greefhorst, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schreurs, A.
Right arrow Articles by Greefhorst, A.
Eur Respir J 1996; 9: 1678-1683
Copyright © ERS Journals Ltd 1996

Clinical Trial

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

AJ Schreurs, HE Sinninghe Damste, CS de Graaff, and AP Greefhorst

The aim of this randomized, double-blind, parallel group study was to determine the lowest effective dose of 6, 12 and 24 microg formoterol fumarate dihydrate Turbuhaler b.i.d. compared with placebo. The 4 week treatment was preceded by a 1 week run-in period. Morning peak expiratory flow (PEF) before intake of the study drug was the primary variable. Patients recorded PEF, prior to and 15 min after intake of the study drug (immediate response), asthma symptoms, and use of rescue medication morning and evening. Of 221 patients (71 females and 150 males), 194 were included in the efficacy per protocol (PP) analysis; mean age 47 yrs, mean forced expiratory volume in one second (FEV1) 2.01 L (58% of predicted), mean FEV1 reversibility 27% at entry. Ninety percent used inhaled steroids. Compared with placebo, 6 microg formoterol b.i.d was found to be the lowest effective dose in the morning (p=0.008) and evening p=0.0041) PEF. The mean increases in PEF were 22 and 23 L x min-1 respectively, compared with placebo. After 6 microg formoterol, the mean immediate increase in morning PEF was 42 L x min-1 compared to an increase of only 9 L x min-1 after placebo (<0.0001). All doses produced a statistically significant decrease in asthma symptoms, day and night, and the need for rescue medication at night. All doses were well-tolerated. In conclusion, the lowest effective dose in this study was formoterol Turbuhaler 6 microg b.i.d.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
A. R. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, and O. Selroos
Formoterol Turbuhaler as reliever medication in patients with acute asthma
Eur. Respir. J., April 1, 2006; 27(4): 735 - 741.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Jenkins
Formoterol as relief medication in asthma: the jury is still out
Eur. Respir. J., November 1, 2003; 22(5): 723 - 724.
[Full Text] [PDF]

Home page
 ChestHome page
U. G. Lalloo, J. Malolepszy, D. Kozma, K. Krofta, J. Ankerst, B. Johansen, and N. C. Thomson
Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma
Chest, May 1, 2003; 123(5): 1480 - 1487.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.W. Ind, C. Villasante, R.J. Shiner, A. Pietinalho, N.G. Boszormenyi, S. Soliman, and O. Selroos
Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma
Eur. Respir. J., October 1, 2002; 20(4): 859 - 866.
[Abstract] [Full Text] [PDF]

Home page
 Fam PractHome page
M. Eccles, N. Rousseau, B. Higgins, and L. Thomas
Evidence-based guideline on the primary care management of asthma
Fam. Pract., April 1, 2001; 18(2): 223 - 229.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.